Combination of Prednisone, Cobalamin, Lomustine, and Radiation Therapy for Treatment of Feline Gastrointestinal Lymphoblastic Lymphoma (FGLL)
Feline gastrointestinal (GI) lymphoblastic lymphoma (FGLL) is a debilitating disease of older cats. Chemotherapy for treatment of FGLL has been used with limited success and long-term survival is uncommon. Radiation therapy (RT) is used to treat localized lymphoma in humans and in two small studies of cats with lymphoma confined to the intestinal tract treated with RT, clinical signs improved in most cats.
The purpose of this study is to determine whether the addition of abdominal cavity RT to oral chemotherapy (lomustine), daily oral prednisone, and weekly parenteral cobalamin will improve response to therapy, survival times, and quality of life of affected cats. If the addition of RT improves outcome, this therapy may be adopted as the standard of care for cats with FGLL and may be used to further study the use of RT for lymphocytic lymphoma and inflammatory bowel disease.
Cats will receive 2 doses of RT and 4 doses of chemotherapy as part of the study. Cats will be expected to return to NC State at weeks 1, 2, 3, 6, 9 and 12 (a total of 6 visits after initial consultation and staging).
- Cats with a cytologic or histologic diagnosis of FGLL (to include stomach, small intestine, large intestine, pancreas, mesenteric lymph nodes, and/or liver)
An expected survival of > 3 weeks regardless of therapy
- Baseline ALT and total bilirubin < 2 x baseline
- The cost of the study medications (lomustine, cobalamin, prednisone), physical exams, blood work, daytime hospitalization, radiology, radiation and chemotherapy will be paid by the study.
- Owner is responsible for covering the costs of baseline diagnostics required as part of the study, with all tests being done at NC State University College of Veterinary Medicine. The cost for these baseline tests may range from ~$400 to ~$750, depending on what type of workup was done at their RDVM.
Page last updated August 12, 2014